Cardiac Electrophysiology Consulting
Physician-led consulting for investors navigating the EP landscape and practices seeking operational excellence — from someone who has spent 6+ years doing the work.
Start a conversation →Clinical Specialization
Cardiac Electrophysiology — one of medicine's fastest-evolving and best-capitalized fields, at the intersection of technology, innovation, and patient outcomes.
What I Do
Gain a practicing electrophysiologist's lens on the EP investment landscape. I help venture funds, private equity, and individual investors evaluate which technologies are clinically viable — and which are overhyped. From pulsed field ablation (FARAPULSE, PulseSelect, VARIPULSE) to LAA occlusion devices (Watchman, Amulet) to subcutaneous ICDs, I translate what I see in the lab into actionable investment signal.
For InvestorsEP labs are high-complexity, high-margin environments — but inefficiency is pervasive. I work with practices and health systems to streamline workflows, reduce case cancellations, improve scheduling, and guide thoughtful adoption of new technologies. The goal: more procedures, less friction, and a team that isn't burning out.
For EP PracticesNeed a credible clinical voice? I provide diligence support, advisory board participation, expert commentary, and speaking engagements for organizations that need authoritative EP insight delivered clearly to non-clinical audiences.
Advisory & SpeakingThe Opportunity
Cardiac electrophysiology is no longer a niche subspecialty — it is one of the most capital-intensive and fastest-growing segments in all of medical technology. Driven by an aging population, an explosion in atrial fibrillation diagnoses, and a wave of breakthrough device innovations, the EP field is attracting billions in investment and reshaping how cardiovascular care is delivered worldwide.
Understanding where that capital flows — and why — requires more than reading market reports. It requires knowing what physicians actually use, what patients actually need, and what technologies truly work. That is where Dr. Luni's consulting practice begins.
PFA is the most significant shift in ablation technology in a generation. Boston Scientific's EP segment grew over 130% in a single quarter after FARAPULSE launched. Abbott's VARIPULSE, J&J's platform, and Medtronic's PulseSelect are all competing for market share.
The Watchman FLX (Boston Scientific) and Amulet (Abbott) devices represent a fast-growing alternative to lifelong anticoagulation in AF patients at bleeding risk. A high-margin, high-growth product category with important clinical nuances only experienced operators can assess.
The subcutaneous ICD market is expanding as physicians and patients seek alternatives to transvenous leads. Paired with the rise of leadless pacing, this segment is drawing substantial R&D investment from Medtronic, Boston Scientific, and emerging players.
Over 12 million Americans are currently affected by atrial fibrillation. The AHA projects nearly 45% of the U.S. population will have some form of cardiovascular disease by 2035. Catheter-based EP procedures among Medicare patients more than doubled between 2013 and 2019.
"There are fewer than 2,600 board-certified electrophysiologists in the United States. That scarcity — of both physicians and genuine clinical insight — is precisely what makes expert consulting in this space so valuable."
— Faraz Luni MD · Faraz Luni MD Consulting PLLCAbout
I'm Dr. Faraz Luni, a board-certified cardiac electrophysiologist with over six years of EP practice. My clinical work spans complex arrhythmia management, catheter ablation (AF, atrial flutter, SVT, and ventricular tachycardia), left atrial appendage occlusion with Watchman and Amulet, subcutaneous and transvenous ICD implantation, leadless pacing, and CRT.
I built my procedural volume and clinical systems at Revere Health, one of Utah's largest private practices, where I generated 22,000 wRVUs in 2024 — placing me in the top 5-10% of electrophysiologists nationally. I left in November 2025 to serve as Director of the EP Lab at Timpanogos Regional Hospital (HCA), where I am building a de novo EP program from the ground up.
Through Faraz Luni MD Consulting PLLC, I bring this frontline operational experience to investors making capital allocation decisions and EP practices looking to run leaner, higher-volume, more sustainable programs.
Research
Insights
Selected Work
Investment Diligence
Provided clinical diligence for an investment group evaluating PFA platforms entering the U.S. market. Assessed technology differentiation, adoption barriers, and competitive positioning across FARAPULSE, PulseSelect, and VARIPULSE.
Practice Optimization
Worked with a regional cardiology group to reduce case cancellation rates and improve lab utilization. Identified workflow bottlenecks and restructured scheduling protocols to increase procedural volume without adding staff.
Market Intelligence
Produced a head-to-head clinical assessment of Watchman FLX vs. Amulet for a fund evaluating structural heart investments — covering implant technique, patient selection, reimbursement trajectory, and real-world outcomes.
Advisory
Served as a founding clinical advisor for an early-stage EP device company, providing feedback on product design, use-case prioritization, patient selection criteria, and early clinical trial strategy.
Get in Touch
Whether you're evaluating an EP investment or looking to sharpen your practice, let's talk. All engagements are confidential.